A short-term study found that oral glucosamine supplementation is not associated with a lessening of knee cartilage deterioration among individuals with chronic knee pain. Findings published in Arthritis & Rheumatology, a journal of the American College of Rheumatology (ACR) journal, indicate that glucosamine does not decrease pain or improve knee bone marrow lesions--more commonly known as bone bruises and thought to be a source of pain in those with osteoarthritis (OA).
According to the ACR 27 million Americans over 25 years of age are diagnosed with OA--the most common form or arthritis and primary cause of disability in the elderly. Patients may seek alternative therapies to treat joint pain and arthritis, with prior research showing glucosamine as the second most commonly-used natural product. In fact, a 2007 Gallup poll reports that 10% of individuals in the U.S. over the age of 18 use glucosamine, with more than $2 billion in global sales of the supplement.
For this double-blind, placebo-controlled trial, Dr. C. Kent Kwoh from the University of Arizona in Tucson and colleagues, enrolled 201 participants with mild to moderate pain in one or both knees. Participants were randomized and treated daily with 1500 mg of a glucosamine hydrochloride in a 16-ounce bottle of diet lemonade or placebo for 24 weeks. Magnetic resonance imaging (MRI) was used to assess cartilage damage.
Trial results show no decrease in cartilage damage in participants in the glucosamine group compared to the placebo group. Researchers report no change in bone marrow lesions in 70% of knees, 18% of knees worsened and 10% improved. The control group had greater improvement in bone marrow lesions compared to treated participants, with neither group displaying a worsening of bone marrow lesions. Glucosamine was not found to decrease urinary excretion of C-telopeptides of type II collagen (CTX-II)--a predictor of cartilage destruction.
The joints on glucosamine (JOG) study is the first to investigate whether the supplement prevents the worsening of cartilage damage or bone marrow lesions. Dr. Kwoh concludes, "Our study found no evidence that drinking a glucosamine supplement reduced knee cartilage damage, relieved pain, or improved function in individuals with chronic knee pain."
This study was funded by the Beverage Institute for Health & Wellness, The Coca-Cola Company and the National Institute of Arthritis, Musculoskeletal and Skin Diseases (P60 AR054731).
This study is published in Arthritis & Rheumatology. Media wishing to receive a PDF of this article may contact firstname.lastname@example.org.
Full citation: "The Joints on Glucosamine (Jog) Study: The Effect of Oral Glucosamine on Joint Structure, A Randomized Trial." C. Kent Kwoh, Frank W. Roemer, Michael J. Hannon, Carolyn E. Moore, John M. Jakicic, Ali Guermazi, Stephanie M. Green, Rhobert W. Evans and Robert Boudreau. Arthritis & Rheumatology; Published Online: March 11, 2014 (DOI: 10.1002/art.38314).
URL Upon Publication: http://doi.
About the Author: To arrange an interview with Dr. Kwoh, please contact Jean Spinelli with the University of Arizona at email@example.com.
About the Journal
Arthritis & Rheumatology is an official journal of the American College of Rheumatology (ACR) and covers all aspects of inflammatory disease. The American College of Rheumatology (http://www.
Wiley is a global provider of content-enabled solutions that improve outcomes in research, education, and professional practice. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners.
Founded in 1807, John Wiley & Sons, Inc. (NYSE: JWa, JWb), has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company's website can be accessed at http://www.